Influenza - Revision history

Danbot: Strip excess bold

2026-03-22T09:38:42Z

Strip excess bold

← Older revision		Revision as of 09:38, 22 March 2026
Line 127:		Line 127:

	====Dosing====		====Dosing====
	*~~'''~~Age <1 year:~~'''~~ 3mg/kg PO BID x 5 days		*Age <1 year: 3mg/kg PO BID x 5 days
	*~~'''~~<15kg:~~'''~~ 30mg PO BID x 5 days		*<15kg: 30mg PO BID x 5 days
	*~~'''~~15-23kg:~~'''~~ 45mg PO BID x 5 days		*15-23kg: 45mg PO BID x 5 days
	*~~'''~~24-40kg:~~'''~~ 60mg PO BID x5d		*24-40kg: 60mg PO BID x5d
	*~~'''~~Adult:~~'''~~ 75mg PO BID x 5 days		*Adult: 75mg PO BID x 5 days

	===[[Zanamivir]] (Relenza)===		===[[Zanamivir]] (Relenza)===
Line 137:		Line 137:

	====Dosing====		====Dosing====
	*~~'''~~Age >7yo:~~'''~~ 10mg (2 inhalations) BID x 5d		*Age >7yo: 10mg (2 inhalations) BID x 5d
	*~~'''~~Prophylaxis:~~'''~~ 10mg (2 inhalations) once daily x 7 days		*Prophylaxis: 10mg (2 inhalations) once daily x 7 days
	**Not for age < 5yo		**Not for age < 5yo

Line 145:		Line 145:

	====Dosing====		====Dosing====
	*~~'''~~Weight between 40-80kg:~~'''~~ 40mg PO once (20 mg tab x2)		*Weight between 40-80kg: 40mg PO once (20 mg tab x2)
	*~~'''~~Weight >80kg:~~'''~~ 80mg PO once (40mg tab x2)		*Weight >80kg: 80mg PO once (40mg tab x2)
	*~~'''~~Prophlyaxis:~~'''~~ not yet approved for this indication by CDC or FDA		*Prophlyaxis: not yet approved for this indication by CDC or FDA

	===NOT Indicated===		===NOT Indicated===
	*Amantadine and other M2 viral proton channel blockers are ~~'''~~no longer indicated for influenza treatment~~'''~~ due to nearly 100% resistance		*Amantadine and other M2 viral proton channel blockers are no longer indicated for influenza treatment due to nearly 100% resistance

	==Disposition==		==Disposition==

Elcatracho: /* Complications */

2021-02-01T21:51:21Z

Complications

← Older revision		Revision as of 21:51, 1 February 2021
Line 165:		Line 165:
	****Higher fever, productive cough, radiographic evidence of infiltrates		****Higher fever, productive cough, radiographic evidence of infiltrates
	***Microbiology		***Microbiology
	****[[Pneumococcus]], [[S. aureus]] (including [[MRSA]]), H. ~~flu~~		****[[Pneumococcus]] and [[S. aureus]] (including [[MRSA]]) most common (35% and 28%, respectively)<ref>Klein EY, Monteforte B, Gupta A, et al. The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. Influenza Other Respir Viruses. 2016;10(5):394-403. doi:10.1111/irv.12398</ref>
			*****[[MRSA]] associated with necrotizing cavitary infections with high mortality rate in previously healthy young people<ref>Centers for Disease Control and Prevention (CDC). Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza--Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep. 2007;56(14):325-329.</ref><ref>Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis. 2006;12(6):894-899. doi:10.3201/eid1206.051141</ref>
	*[[Otitis Media]]		*[[Otitis Media]]
	**More common in children		**More common in children

Rossdonaldson1: /* Management */

2020-03-10T21:41:22Z

Management

← Older revision		Revision as of 21:41, 10 March 2020
Line 81:		Line 81:

	==Management==		==Management==
	''Despite questions on efficacy and safety, CDC still recommends treatment for all hospitalized patients and outpatients at risk for complications<ref>Fiore AE, et al. Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). CDC. Recommendations and Reports. January 21, 2011. 60(RR01);1-24.</ref>''

	===[[Isolation Precautions]]===		===[[Isolation Precautions]]===
	*Droplet precautions		*Droplet precautions
Line 88:		Line 86:

	===Antiviral Treatment===		===Antiviral Treatment===
			''Despite questions on efficacy and safety, CDC still recommends treatment for all hospitalized patients and outpatients at risk for complications<ref>Fiore AE, et al. Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). CDC. Recommendations and Reports. January 21, 2011. 60(RR01);1-24.</ref>''
	{\| class="wikitable"		{\| class="wikitable"
	\| align="center" style="background:#f0f0f0;"\|'''Antiviral Agent'''		\| align="center" style="background:#f0f0f0;"\|'''Antiviral Agent'''

Rossdonaldson1: /* Evaluation */

2020-03-10T21:41:01Z

Evaluation

← Older revision		Revision as of 21:41, 10 March 2020
Line 57:		Line 57:
	*Rapid tests specific but not sensitive (cannot be used to rule-out)		*Rapid tests specific but not sensitive (cannot be used to rule-out)

	===~~Evaluation~~===		===Diagnosis===
	====Outpatients====		====Outpatients====
	*Risk factors:		*Risk factors:

Rossdonaldson1: /* Dosing */

2020-03-10T21:40:02Z

Dosing

← Older revision		Revision as of 21:40, 10 March 2020
Line 145:		Line 145:
	''Only approved for patients >12 years old and >40kg in weight, no current safety data exists for pregnancy and breastfeeding.<ref>https://www.cdc.gov/flu/treatment/baloxavir-marboxil.htm</ref> More expensive but one time dosing. Genentech, its creator, states a recent phase III trial has shown it to be effective for prophylaxis but not currently FDA indicated for this.<ref>https://www.gene.com/download/pdf/xofluza_prescribing.pdf</ref>		''Only approved for patients >12 years old and >40kg in weight, no current safety data exists for pregnancy and breastfeeding.<ref>https://www.cdc.gov/flu/treatment/baloxavir-marboxil.htm</ref> More expensive but one time dosing. Genentech, its creator, states a recent phase III trial has shown it to be effective for prophylaxis but not currently FDA indicated for this.<ref>https://www.gene.com/download/pdf/xofluza_prescribing.pdf</ref>

	===Dosing===		====Dosing====
	*'''Weight between 40-80kg:''' 40mg PO once (20 mg tab x2)		*'''Weight between 40-80kg:''' 40mg PO once (20 mg tab x2)
	*'''Weight >80kg:''' 80mg PO once (40mg tab x2)		*'''Weight >80kg:''' 80mg PO once (40mg tab x2)

Rossdonaldson1: /* M2 Channel Blocker */

2020-03-10T21:35:18Z

M2 Channel Blocker

← Older revision		Revision as of 21:35, 10 March 2020
Line 150:		Line 150:
	*'''Prophlyaxis:''' not yet approved for this indication by CDC or FDA		*'''Prophlyaxis:''' not yet approved for this indication by CDC or FDA

	===~~M2 Channel Blocker~~===		===NOT Indicated===
	*Amantadine and other M2 viral proton channel blockers are '''no longer indicated for influenza treatment''' due to nearly 100% resistance		*Amantadine and other M2 viral proton channel blockers are '''no longer indicated for influenza treatment''' due to nearly 100% resistance

Rossdonaldson1: /* Antiviral Treatment */

2020-03-10T21:34:37Z

Antiviral Treatment

← Older revision		Revision as of 21:34, 10 March 2020
Line 94:		Line 94:
	\| align="center" style="background:#f0f0f0;"\|'''Adverse Events'''		\| align="center" style="background:#f0f0f0;"\|'''Adverse Events'''
	\|-		\|-
	\| Oseltamivir (Tamiflu®)		\| [[Oseltamivir]] (Tamiflu®)
	\|\|		\|\|
	*Treatment: any age		*Treatment: any age
Line 102:		Line 102:
	*Adverse events: nausea, vomiting. Sporadic, transient neuropsychiatric events (self-injury or delirium) mainly reported among Japanese adolescents and adults.		*Adverse events: nausea, vomiting. Sporadic, transient neuropsychiatric events (self-injury or delirium) mainly reported among Japanese adolescents and adults.
	\|-		\|-
	\| Zanamivir (Relenza®)		\| [[Zanamivir]] (Relenza®)
	\|\|		\|\|
	*Treatment: >7 yrs		*Treatment: >7 yrs
Line 111:		Line 111:
	*Adverse events: diarrhea, nausea, sinusitis, nasal signs and symptoms, bronchitis, cough, headache, dizziness, and ear, nose and throat infections.		*Adverse events: diarrhea, nausea, sinusitis, nasal signs and symptoms, bronchitis, cough, headache, dizziness, and ear, nose and throat infections.
	\|-		\|-
	\|Baloxavir marboxil (Xofluza®)		\|[[Baloxavir marboxil]] (Xofluza®)
	\|\|		\|\|
	*Treatment: >12 years		*Treatment: >12 years

Rossdonaldson1: /* Management */

2020-03-10T21:34:16Z

Management

@@ Line 87: / Line 87: @@
 **If the patient is in an area in which they are in contact with other patients or need to be transported and thus may come in close contact (<3 feet) with staff, visitors, or other patients, the patient needs to wear a surgical mask (or N-95 respirator, if not available).
-===[[Oseltamivir]] (Tamiflu)===
+===Antiviral Treatment===
 {| class="wikitable"
 | align="center" style="background:#f0f0f0;"|'''Antiviral Agent'''
@@ Line 148: / Line 120: @@
 *Allergic reactions: oropharyngeal or facial edema
 |}
 ===M2 Channel Blocker===

Rossdonaldson1: /* Management */

2020-03-10T21:31:27Z

Management

← Older revision		Revision as of 21:31, 10 March 2020
Line 82:		Line 82:
	==Management==		==Management==
	''Despite questions on efficacy and safety, CDC still recommends treatment for all hospitalized patients and outpatients at risk for complications<ref>Fiore AE, et al. Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). CDC. Recommendations and Reports. January 21, 2011. 60(RR01);1-24.</ref>''		''Despite questions on efficacy and safety, CDC still recommends treatment for all hospitalized patients and outpatients at risk for complications<ref>Fiore AE, et al. Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). CDC. Recommendations and Reports. January 21, 2011. 60(RR01);1-24.</ref>''

			===[[Isolation Precautions]]===
			*Droplet precautions
			**If the patient is in an area in which they are in contact with other patients or need to be transported and thus may come in close contact (<3 feet) with staff, visitors, or other patients, the patient needs to wear a surgical mask (or N-95 respirator, if not available).

	===[[Oseltamivir]] (Tamiflu)===		===[[Oseltamivir]] (Tamiflu)===
Line 147:		Line 151:
	===M2 Channel Blocker===		===M2 Channel Blocker===
	*Amantadine and other M2 viral proton channel blockers are '''no longer indicated for influenza treatment''' due to nearly 100% resistance		*Amantadine and other M2 viral proton channel blockers are '''no longer indicated for influenza treatment''' due to nearly 100% resistance

	~~===[[Isolation Precautions]]===~~
	*Droplet precautions
	**If the patient is in an area in which they are in contact with other patients or need to be transported and thus may come in close contact (<3 feet) with staff, visitors, or other patients, the patient needs to wear a surgical mask (or N-95 respirator, if not available).

	==Disposition==		==Disposition==

Rossdonaldson1: /* Complications */

2020-03-10T21:30:42Z

Complications

← Older revision		Revision as of 21:30, 10 March 2020
Line 151:		Line 151:
	*Droplet precautions		*Droplet precautions
	**If the patient is in an area in which they are in contact with other patients or need to be transported and thus may come in close contact (<3 feet) with staff, visitors, or other patients, the patient needs to wear a surgical mask (or N-95 respirator, if not available).		**If the patient is in an area in which they are in contact with other patients or need to be transported and thus may come in close contact (<3 feet) with staff, visitors, or other patients, the patient needs to wear a surgical mask (or N-95 respirator, if not available).

			==Disposition==

	==Complications==		==Complications==